Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCTNCT06779929 (opens ClinicalTrials.gov in a new tab)Other id2024P001317
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase not stated
Enrollment
70,000 participants (actual)
Sponsor
Brigham and Women's Hospital · Other
Design
Not stated
Countries
1 country

United States

Start
1 Nov 2024
Primary completion
1 Dec 2025
Completion
1 Mar 2026
First posted
17 Jan 2025
Last update posted
18 Sept 2026
Conditions
Type 2 Diabetes

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2024202520262027
  1. Ph –

    Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

    NCT06779929

    1 Nov 2024 to 1 Mar 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.

Interventions

  • TirzepatideDrug
  • DulaglutideDrug
  • SemaglutideDrug

Arms3

  • Other

    Tirzepatide

    Patients who initiated tirzepatide with no use in the prior 180 days

  • Other

    Dulaglutide

    Patients who initiate dulaglutide with no use in the prior 180 days

  • Other

    Semaglutide

    Patients who initiate semaglutide with no use in the prior 180 days

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Composite CV outcome

    Time frame · From treatment initiation to end of follow up, up to 48 months.

    Registry description

    Composite CV outcome includes myocardial infarction, stroke, and all-cause mortality.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

PubMed tag: none · 2026

8 results

Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.

Ostrominski et al. 2026Diabetes carecited by 1

PMID 41778928PMC13241951DOI 10.2337/dc25-3063PUB-41778928

Rights unknown8 results
Source linkSee results (8)

Indexing hint: Clinical trial · 2024

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.

Nicholls et al. 2024American heart journalcited by 197

PMID 37758044DOI 10.1016/j.ahj.2023.09.007PUB-37758044

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
from 40 Years
Healthy volunteers
Not stated
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Patients with T2D who were new users of tirzepatide or new users of dulaglutide * AND established ASCVD defined as: * History of Myocardial Infarction (MI) or MI sequela * Unstable or stable angina * Coronary atherosclerosis disease or procedures * Ischemic stroke * Peripheral arterial disease or procedures * Atherosclerotic cerebrovascular disease or cerebrovascular procedures * Lower-limb amputation * Age \>= 40 years old * Patients with at least 180 days of continuous health plan enrollment before and including the treatment initiation date Exclusion Criteria: * Patients with Type 1 diabetes mellitus * Patients with missing age or sex information * Patients with history of proliferative diabetic retinopathy, panretinal photocoagulation, vitreous hemorrhage, or intravitreal anti-VEGF injection * Patient within history of left ventricular assisted device (LVAD) or heart transplant * Patients with any previous organ transplants * Patients with acute of chronic pancreatitis * Patients with gastroparesis, bowel obstruction or bariatric surgery * Patient with CKD Stage 5, end stage kidney disease, kidney transplant, or hemodialysis * Patients with multiple endocrine neoplasm syndrome type 2 (MEN-2) * Patient with cancer * Pregnant women * Patient with diabetic ketoacidosis or HONK within the last year to treatment initiation * Patients with acute hepatitis within the last year to treatment initiation * Patients with elevated serum calcitonin level within the last year to treatment initiation * Previous exposure to GLP-1RA or pramlintide during the 180-days washout period and including treatment initiation date * Patients with severe hypoglycemia within the last 6 months to treatment initiation * Patients with hospitalization for heart failure within the last 60 days to treatment initiation * Patient with acute coronary syndrome, ischemic stroke, peripheral arterial disease, or coronary or cerebrovascular procedure within the last 60 days to treatment initiation * Patients with prescription dispensing for both tirzepatide and dulaglutide on treatment initiation date

PepBank is a research reference. Talk to a doctor before you use any peptide.